Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 44

Results For "CAS"

1927 News Found

Alkem reports 7.1% YoY revenue growth in Q4 FY25
News | May 30, 2025

Alkem reports 7.1% YoY revenue growth in Q4 FY25

Annual EBITDA margin expands by 170 basis points


Granules India posts Q4 FY25 PAT at Rs. 152 Cr
News | May 28, 2025

Granules India posts Q4 FY25 PAT at Rs. 152 Cr

The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility


Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr
News | May 28, 2025

Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr

Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year


Zydus Lifesciences’ ‘breast cancer awareness campaign reaches millions
News | May 27, 2025

Zydus Lifesciences’ ‘breast cancer awareness campaign reaches millions

Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness


CPHI & PMEC China sees surge in international attendance
News | May 24, 2025

CPHI & PMEC China sees surge in international attendance

Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth


Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP
Drug Approval | May 24, 2025

Indoco Remedies receives final approval from the USFDA for Allopurinol Tablets USP

Allopurinol is used to prevent or lower high uric acid levels in the blood


Venus Remedies secures Ukrainian GMP renewal
News | May 23, 2025

Venus Remedies secures Ukrainian GMP renewal

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards


Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
News | May 18, 2025

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis


Bayer confirms 2025 targets after solid start to the year
News | May 14, 2025

Bayer confirms 2025 targets after solid start to the year

EBITDA before special items decreases to €4.08 billion (7.4%)